* Novartis ' one-third stake in Roche built up under Vasella
ZURICH, May 16 (Reuters) - Novartis has no plans to bid for U.S.-based generic drugmaker Actavis, which is the subject of intense takeover speculation, a spokesman for the Swiss drugmaker said on Thursday.
which has rebuffed overtures from both Valeant ( VRX ) and more recently Mylan ( MYL ), may soon receive a bid from Novartis ( NVS ), WSJ says. "Intense price competition and fewer opportunities to cash in on patent expirations," are fueling
infections. In an exhaustive rundown, SA contributor Scott Matusow claims the drug is a superior alternative to Novartis ' ( NVS ) TOBI for a number of reasons and also says INSM could capture a significant portion of the $424M (annually) market
entered the market in Europe, led by Novartis ' Sandoz division. These biosimilars ..... with established drugs such as Novartis ' Reclast and cheaper generic bisphosphonates ..... so far indicates superiority to Novartis ' NVS blockbuster Zometa. We believe
novel oral therapies, such as Novartis ' Gilenya and Sanofi's Aubagio ..... Tecfidera's growth trajectory given Novartis ' first-mover advantage in the ..... established injectable drugs and Novartis ' NVS oral multiple sclerosis drug Gilenya
of Medical Products, spent 14 years at Lilly; and Ludwig Hantson, head of BioScience, spent more than 20 years at Novartis and Johnson & Johnson. Overall, we think Baxter's capital allocation strategy (split relatively evenly between capital
pooled voting rights--including board members Andre Hoffmann and Andreas Oeri--owns 45% of voting shares, and Novartis owns 33% of voting shares. Roche is a Swiss biopharmaceutical and diagnostic company. The firm's best-selling pharmaceutical
candidates for the treatment of cancers and other diseases. The first article looked at Array's collaboration with Novartis ( NVS ) , Amgen ( AMGN ) , AstraZeneca ( AZN ) and other companies that are developing some promising therapies. This article
LONDON, May 10 (Reuters) - European shares scaled fresh five-year highs on Friday, led by healthcare group Novartis and telecoms firm BT on positive corporate news, and traders said key indexes had...